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Abstract 26 
Multiple Myeloma (MM) is a haematologic malignancy characterised by the 27 
accumulation of clonal plasma cells in the bone marrow. Over the last 10-15 years 28 
the introduction of the proteasome-inhibitor bortezomib has improved MM prognosis, 29 
however relapse due to bortezomib-resistance is inevitable and the disease, at 30 
present, remains incurable. To model bortezomib-resistant MM we generated 31 
bortezomib-resistant MM cell lines (n=4) and utilised primary malignant plasma cells 32 
from patients relapsing after bortezomib treatment (n=6). We identified enhanced 33 
Bruton’s tyrosine kinase (BTK) activity in bortezomib-resistant MM cells and found 34 
that inhibition of BTK, either pharmacologically with ibrutinib (0.5 μM) or via lenti-viral 35 
miRNA-targeted BTK interference, re-sensitised previously bortezomib-resistant MM 36 
cells to further bortezomib therapy at a physiologically relevant concentration (5 nM). 37 
Further analysis of pro-survival signalling revealed a role for the NF-κB p65 subunit 38 
in MM bortezomib-resistance, thus a combination of BTK and NF-κB p65 inhibition, 39 
either pharmacologically or via further lenti-viral miRNA NF-κB p65 interference, also 40 
restored sensitivity to bortezomib, significantly reducing cell viability (37.5±6.9 %, 41 
ANOVA p≤0.001). Accordingly, we propose the clinical evaluation of a 42 
bortezomib/ibrutinib combination therapy, including in patients resistant to single-43 
agent bortezomib.                  44 
45 
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Introduction 46 
Multiple Myeloma (MM) is characterised by the accumulation of clonal plasma cells 47 
in the bone marrow. The American Cancer Society estimates that there will be 48 
approximately 24,000 new cases diagnosed and 11,000 deaths from MM in 2014 in 49 
the US.{, 2014 #8628} Clinical manifestations of the disease occur as a 50 
consequence of the tumour bulk; including anaemia and fatigue, immune paresis 51 
leading to infection, renal failure, and osteolytic bone breakdown by activated 52 
osteoclasts, resulting in painful lytic bone destruction and hypercalcaemia.{Raab, 53 
2009 #6283} An effective MM therapeutic succeeds, therefore, by ‘de-bulking’ the 54 
MM tumour mass, thus reducing the associated symptoms and subsequently 55 
maintaining remission.  56 
The proteasome inhibitor (PI) bortezomib, approved for the treatment of MM by the 57 
FDA in 2003{Twombly, 2003 #8549}, is one such de-bulking agent that has greatly 58 
contributed to improved outcomes observed in MM.{Palumbo, 2011 #8529} Despite 59 
this advance, however, relapse following bortezomib therapy remains inevitable due 60 
to the emergence of bortezomib-resistant plasma cell sub-clones.{Kapoor, 2012 61 
#8550} For example; recent ‘whole genome’ sequencing studies of MM patients 62 
confirmed a high level of genetic heterogeneity; occurring both between separate 63 
patients, and within patient samples before and after therapy{Chapman, 2011 64 
#5683}, indicating the presence of a variety of genetically distinct plasma cell ‘sub-65 
clones’.{Egan, 2012 #8564;Keats, 2012 #8566} Different sub-clones further indicate 66 
the presence of numerous minor tumour initiating cell populations with complex and 67 
divergent evolutionary histories.{Magrangeas, 2013 #8666} The diversity and 68 
potential quiescence of these MM sub-clones can contribute to enhanced 69 
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tumorigenicity and an intrinsic resistance to therapy.{Chen, 2014 #8667} Therefore; 70 
the eradication of the majority bortezomib-sensitive sub-clones may ultimately 71 
promote the growth of pre-existing minority bortezomib-resistant sub-clones, limiting 72 
the efficacy of single-agent bortezomib. This finding is further supported by the 73 
clinical observation that approximately half of initially bortezomib-sensitive MM 74 
patients are no longer able to respond to bortezomib once relapsed.{Lonial, 2011 75 
#8554} This sub-clonal bortezomib-resistance has been attributed to a range of 76 
mechanisms; including enhanced growth factor expression{Kuhn, 2012 #8558}, 77 
mutated proteasome subunits{Oerlemans, 2008 #5368}, deregulated plasma cell 78 
maturation markers{Stessman, 2013 #8553}, and nuclear factor-kappa B (NF-κB) 79 
pathway ‘addiction’{Annunziata, 2007 #5684} [for a more in-depth exploration of this 80 
topic see Murray et al. 2014{Murray, 2014 #8633}]. Furthermore, pro-survival NF-κB 81 
signalling pathway members were also found to have a broader than anticipated 82 
profile in MM whole genome sequencing data.{Chapman, 2011 #5683} These 83 
findings are consistent with our previous studies into the role of NF-κB signalling in 84 
haematological malignancies{Rushworth, 2013 #6375;Murray, 2013 85 
#8580;Rushworth, 2012 #6377}, suggesting that a greater understanding of the NF-86 
κB signaling network in bortezomib-resistant MM may be central to achieving 87 
therapeutic advances in this disease. 88 
In its primary mode of action bortezomib successfully inhibits ‘inducible’ NF-κB 89 
expression in MM cells, such as the expression stimulated by MM-bone marrow 90 
stromal cell (BMSC) interaction{Chauhan, 1996 #8481}, via its function as an 91 
inhibitor of the 20s proteasome β5 subunit.{Lu, 2013 #8629} Conversely, however, 92 
bortezomib also enhances ‘constitutive’ levels of NF-κB through activation of IKKβ, 93 
ultimately leading to NF-κB nuclear translocation and the transcription of multiple NF-94 
6 
 
κB-induced genes, including Bruton’s tyrosine kinase (BTK).{Yu, 2008 #8527} BTK, 95 
a non-receptor tyrosine kinase, is now known to be of key importance to a number of 96 
haematological malignancies, including MM{Tai, 2012 #8198}, chronic lymphocytic 97 
leukemia (CLL){O'Brien, 2012 #8167} and acute myeloid leukemia 98 
(AML).{Rushworth, 2014 #8589} The potential feedback mechanism between NF-κB 99 
and BTK signalling, whereby BTK also lies upstream of several NF-κB inducible 100 
signalling pathways{Khan, 2001 #8247;Jefferies, 2004 #8630}, provides a rationale 101 
for investigation of combined NF-κB and BTK inhibition in MM.  102 
Previously we and others have shown ex vivo efficacy of BTK inhibition in MM.{Tai, 103 
2012 #8198;Rushworth, 2013 #6375} Specifically, we have shown that the 104 
irreversible BTK inhibitor ibrutinib can enhance the action of bortezomib via 105 
repression of the NF-κB survival pathway in primary tissue, e.g., bone marrow-106 
derived MM cells from treatment-naïve patients.{Rushworth, 2013 #6375} Despite 107 
these findings, however, early phase II clinical trial data for ibrutinib monotherapy in 108 
MM have so far proved disappointing{Pharmacyclics, 2012 #8523}, whilst the study 109 
of ibrutinib efficacy in patients with relapsed of refractory MM is currently recruiting 110 
(ClinicalTrials.gov Identifier:NCT01478581).  111 
Taken together these data highlight the need to develop novel therapeutic strategies 112 
that can overcome bortezomib-resistance{Murray, 2014 #8633}, whilst still de-113 
bulking the tumour and protecting the patient from related organ and tissue 114 
impairment. 115 
MM clonal development and selection is impacted by the timing, order, and 116 
combinations of therapies received; however, all patients treated with bortezomib 117 
therapy are destined to relapse and become bortezomib-resistant. Here, we utilise in 118 
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vitro modelling to demonstrate BTK pro-survival pathway activity in bortezomib-119 
resistant MM. These data provide justification for further assessment of greater 120 
patient numbers in the clinic, which will establish whether ibrutinib therapy can be 121 
used to overcome bortezomib-resistance in MM in practice. 122 
123 
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 Results 124 
Generation and characterisation of bortezomib-resistant MM cells 125 
To determine the importance of the BTK pro-survival pathway in bortezomib-126 
resistance we first generated bortezomib-resistant cells in vitro. We cultured MM-127 
derived B lymphocytic cell lines (H929, LP-1, RPMI-8226, and U266) in the 128 
continuous presence of bortezomib, increasing bortezomib concentration in stepwise 129 
increments up to 10 nM. Corresponding bortezomib-naïve MM cell lines were used 130 
as a control. Bortezomib-resistance in the cell lines was confirmed by a significant 131 
increase in IC50 log[bortezomib] (Figure 1 A) and enhanced cell viability following 132 
exposure to physiologically relevant{Papandreou, 2004 #8632} levels of bortezomib 133 
[5 nM (Figure 1 B)] when compared to control ‘bortezomib-naïve’ MM cells. In 134 
addition, we explored relative chymotrypsin-like proteasome activity in bortezomib-135 
naïve and bortezomib-resistant MM cell lines and observed significantly higher levels 136 
of proteasome activity in bortezomib-resistant MM cells (Figure 1 C), further 137 
confirming their inability to respond to bortezomib’s proteasome-inhibitor function.  138 
We also analysed primary human treatment-naïve MM patient samples (primary 139 
naïve; n=5) and primary human MM samples from patients that had initially 140 
responded to bortezomib but subsequently relapsed (primary relapsed; n=6). All 141 
primary naïve patient samples analysed (n=5/5) showed significantly reduced cell 142 
viability in response to bortezomib in vitro, whilst the majority (n=4/6) of primary 143 
relapsed samples showed no significant reduction in viability. The remaining (n=2/6) 144 
primary relapsed samples showed significantly decreased cell viability in response to 145 
bortezomib, in-keeping with the clinical observation that approximately half of 146 
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patients retreated with bortezomib will respond again {Taverna, 2012 147 
#8634;Petrucci, 2013 #8635} (Figure 1 D).30,31 148 
Basal BTK activity is enhanced in bortezomib-resistant MM cell lines and is resistant 149 
to inhibition with bortezomib  150 
We have previously shown that the BTK pathway is active in MM.{Rushworth, 2013 151 
#6375} Furthermore, others have shown that bortezomib can reduce the expression 152 
of BTK mRNA and protein via an NF-κB p65-dependent mechanism.{Yu, 2008 153 
#8527} We therefore examined whether BTK expression and activity in bortezomib-154 
resistant MM cell lines reflects a mechanistic change in the BTK pro-survival 155 
signalling pathway in response to bortezomib treatment. We first examined basal 156 
levels of BTK activity in bortezomib-naïve and bortezomib-resistant U266 MM cells 157 
by immunocytochemistry. Utilising antibodies against total BTK (BTK) and Y223-158 
phosphorylated BTK (pBTK) we observed higher levels of pBTK in bortezomib-159 
resistant cells [n ≥ 80] compared to bortezomib-naïve cells, suggesting a greater 160 
level of BTK activity in the resistant cells (Figure 2 A; left panel). Further quantitative 161 
analysis of the immunocytochemistry confirmed significantly enhanced basal pBTK 162 
levels in bortezomib-resistant MM cell lines (Figure 2 A; right panel [n≥20]). We next 163 
examined what effect this enhanced level of basal BTK activity has on bortezomib-164 
resistant MM cell response to further bortezomib exposure. Following bortezomib 165 
treatment (4 h), we observed a significant decrease in relative BTK mRNA in the 166 
bortezomib-naïve but not bortezomib-resistant MM cell lines (Figure 2 B), suggesting 167 
BTK expression is not inhibited by bortezomib treatment in the bortezomib resistant 168 
cells.  169 
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To further investigate this difference in BTK mRNA expression and activity in 170 
bortezomib-resistant MM cells we examined activity of the BTK promoter, utilising a 171 
chemi-luminescent BTK promoter-luciferase reporter construct, specifically 172 
containing two NF-κB transcription factor binding sites [κB1 and κB2]; pGL4.BTK  173 
(Figure 2 C). Following 24 h bortezomib treatment bortezomib-naïve U266 MM cells 174 
transfected with pGL4.BTK showed significantly reduced BTK promoter activity 175 
(Figure 2 D). Conversely, there was no change in BTK promoter activity when 176 
bortezomib-resistant U266 MM cells were transfected with pGL4.BTK, and the level 177 
of BTK promoter activity in these cells remained significantly higher than in 178 
bortezomib-naïve cells exposed to bortezomib. These results demonstrate that the 179 
ability of bortezomib to repress BTK promoter activity is lost in bortezomib-resistant 180 
MM cells.  181 
Pharmacological BTK inhibition with ibrutinib restores sensitivity to bortezomib in 182 
bortezomib-resistant MM cells   183 
As BTK is emerging as an important regulator of downstream survival pathways in 184 
MM{Tai, 2012 #8198;Rushworth, 2013 #6375}, and further to our observations of 185 
enhanced BTK activity and expression in bortezomib-resistant MM cells (Figure 2), 186 
we investigated the functional effect of combined pharmacological BTK inhibition and 187 
bortezomib treatment in bortezomib-naïve and bortezomib-resistant MM cell lines 188 
and primary human MM samples. Ibrutinib ‘pulse’ treatment [0.5 μM/1 h] alone 189 
significantly reduced cell viability in bortezomib-resistant MM cells lines after 48 h 190 
(Figure 3 A). When combined with bortezomib exposure [5 nM/24 h], the ibrutinib 191 
‘pulse’ also significantly reduced cell viability in bortezomib-resistant U266 MM cells 192 
below levels observed in bortezomib-resistant cells receiving bortezomib alone, and 193 
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bortezomib-naïve cells receiving the same combination therapy (Figure 3 B). 194 
Importantly, ibrutinib ‘pulse’ treatment followed by bortezomib exposure also 195 
dramatically reduced cell viability in primary relapsed MM samples [n=6], likewise 196 
below levels observed in primary relapsed samples receiving bortezomib alone, and 197 
primary naïve MM samples [n=5] also receiving the combination therapy (Figure 3 198 
C). 199 
BTK inhibition via lenti-viral miRNA targeting also restores sensitivity to bortezomib 200 
in bortezomib-resistant MM cells 201 
Although originally developed as an inhibitor of BTK, ibrutinib has more recently 202 
been shown to have ‘off-target’ effects, inhibiting multiple members of the TEC 203 
kinase family, including interleukin-2-inducible T-cell kinase (ITK).{Dubovsky, 2013 204 
#8624} Therefore, to ensure our results were not due to potential off-target inhibitor 205 
activity, we evaluated bortezomib-resistant and bortezomib-naïve U266 MM cell line 206 
response to lenti-viral-mediated BTK repression. Specifically, we generated artificial 207 
and exogenous miRNA sequences specifically targeting the BTK transcript [miRBTK] 208 
and utilised lenti-viral infection to achieve semi-stable BTK mRNA knockdown [as 209 
described previously{Rushworth, 2014 #8589}] in both bortezomib-naïve and 210 
bortezomib-resistant U266 MM cells (Figure 4 A). Furthermore, the introduction of 211 
miRBTK in conjunction with bortezomib treatment (5 nM/24 h) confirmed that 212 
bortezomib-resistant U266 MM cells experienced significantly reduced cell viability 213 
compared to bortezomib-naïve cells also infected with miRBTK and exposed to 214 
bortezomib, and compared to bortezomib-resistant cells infected with a non-targeting 215 
control miRNA [miRNEG] (Figure 4 B). This strongly suggests that the results 216 
observed following ibrutinib and bortezomib combination therapy in bortezomib-217 
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resistant cells are due to ibrutinib-driven irreversible BTK inhibition, rather than any 218 
off target ibrutinib effects. 219 
Bortezomib-resistance is driven by enhanced NF-κB p65 activity and can be 220 
reversed by BTK inhibition 221 
We have previously shown that BTK inhibition reduces NF-κB p65 activity in 222 
bortezomib-naïve MM cells and primary naïve patient samples.{Rushworth, 2013 223 
#6375} To determine the role of NF-κB p65 in the regulation of BTK activity in 224 
bortezomib-resistant MM cells we initially examined basal levels of sub-cellular NF-225 
κB p65 protein distribution in bortezomib-naïve and bortezomib-resistant U266 MM 226 
cells by immunocytochemistry. Utilising an antibody against the NF-κB p65 subunit 227 
we observed higher levels p65 in the nucleus of bortezomib-resistant cells compared 228 
to bortezomib-naïve cells [n≥20], suggesting a greater level of NF-κB p65 229 
transcription factor binding, and therefore NF-κB signalling in the bortezomib-230 
resistant cells (Figure 5 A; inset). Further analysis of nuclear vs. cytoplasmic NF-κB 231 
p65 revealed higher basal levels of nuclear localisation in bortezomib-resistant 232 
compared to bortezomib-naïve U266 MM cells; both by quantitative analysis (Figure 233 
5 A) and western immunoblot (Figure 5 B).  Additionally, analysis of sub-cellular NF-234 
κB p65 localisation in response to ibrutinib ‘pulse’ treatment combined with 235 
bortezomib exposure [5 nM/4 h] revealed significant repression of NF-κB p65 nuclear 236 
localisation in bortezomib-resistant and bortezomib-naïve U266 MM cells compared 237 
to those treated with bortezomib alone (Figure 5 C). Importantly, bortezomib-238 
resistant cells showed no significant reduction in NF-κB p65 nuclear localisation in 239 
response to bortezomib treatment alone compared to bortezomib-naïve cells, 240 
potentially suggesting a level of constitutive NF-κB p65 activity in these cells.  241 
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To confirm the functional relevance of enhanced basal nuclear NF-κB p65 242 
localisation in bortezomib-resistant MM cells, and to confirm that any response to 243 
bortezomib observed was specifically due to its ability to repress inducible NF-κB 244 
p65 activity, we generated artificial and exogenous miRNA sequences specifically 245 
targeting NF-κB p65 (miRp65) and utilised lenti-viral infection to achieve semi-stable 246 
p65 mRNA knockdown in bortezomib-naïve and bortezomib-resistant U266 MM cells 247 
(Figure 5 D). Introduction of miRp65, in combination with ibrutinib ‘pulse’ treatment, 248 
significantly reduced cell viability in bortezomib-resistant U266 MM cells compared to 249 
bortezomib-naïve cells exposed to the same treatment, and compared to 250 
bortezomib-resistant cells infected with a non-targeting control miRNEG or ibrutinib 251 
‘pulse’ treatment alone (Figure 5 E). 252 
253 
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Discussion 254 
The proteasome inhibitor bortezomib is licensed to treat newly diagnosed and 255 
relapsed MM in the clinic. Single agent bortezomib has a response rate of 256 
approximately 30% but, when used in combination with chemotherapy and/or 257 
corticosteroids, response rates range from approximately 60% to over 90% 258 
depending on the regimen.{Murray, 2014 #8633} Despite this relative success, 259 
however, clinical relapse following bortezomib therapy presently remains inevitable 260 
and resistance to further bortezomib treatment is common{Taverna, 2012 261 
#8634;Petrucci, 2013 #8635}, not only as a consequence of, but also further driving 262 
the selection and emergence of drug-resistant clones.{Egan, 2012 #8564;Keats, 263 
2012 #8566} An improved understanding of the mechanisms underlying bortezomib-264 
resistance is, therefore, vital for the progressive development of novel pharmacologic 265 
strategies to overcome the clinical phenomenon of bortezomib-resistance. In this 266 
study we have explored bortezomib-resistance in MM in vitro, utilising bortezomib-267 
resistant MM cell lines generated in the laboratory, and primary patient samples from 268 
both treatment naïve patients and patients that have relapsed following bortezomib 269 
therapy.  Despite a the limitsof the sample size, this data provides thefoundation for 270 
future in vivo assessment of ibrutinib treatment of patients with bortezomib-relapsed 271 
MM in a larger numbers of patients in the clinic. 272 
We and others have previously demonstrated activity of the BTK survival pathway in 273 
treatment-naïve MM cells.{Tai, 2012 #6376;Rushworth, 2013 #6375} Furthermore, 274 
bortezomib has been reported to inhibit total BTK expression in a treatment-naive B 275 
lymphocyte cell line.{Yu, 2008 #8527} Here, utilising in vitro models of post-276 
bortezomib relapsed MM, we describe a role for BTK activity in bortezomib-277 
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resistance, demonstrating higher basal levels of active pBTK protein in bortezomib-278 
resistant MM cell lines and a failure of these cells to respond to bortezomib in terms 279 
of BTK mRNA and BTK promoter activity repression. In particular, the higher basal 280 
BTK activity and altered BTK promoter activity in bortezomib-resistant cells would be 281 
consistent with process of clonal selection, driven by constant exposure to 282 
bortezomib.{Keats, 2012 #8566} This identifies BTK as a candidate therapeutic 283 
target in bortezomib-resistant MM. In addition, this may also be relevant to 284 
bortezomib-naïve MM, in which potentially bortezomib-resistant sub-clones as yet 285 
form a minority population within of the tumour ‘bulk’. 286 
The oral BTK inhibitor ibrutinib, currently licenced for use in CLL and 287 
MCL{McDermott, 2014 #8636;Cameron, 2014 #8637}, has shown promising clinical 288 
activity and a favourable side-effect profile in a range of B cell malignancies.{Byrd, 289 
2013 #8638;Wang, 2013 #8477;Advani, 2013 #8640;O'Brien, 2014 #8641} Ibrutinib 290 
has also been found to reduce BTK expression in MM{Yu, 2008 #8527} and enhance 291 
the cytotoxicity of bortezomib in bortezomib-naïve primary malignant plasma cells 292 
and MM cell lines.{Rushworth, 2013 #6375} By inhibiting BTK with ibrutinib ‘pulse’ 293 
treatment we were also able to restore a measurable cytotoxic response to 294 
bortezomib in bortezomib-resistant MM cell lines and primary relapsed MM cells. 295 
Importantly, although ibrutinib is known to target other kinases, we were able to 296 
reproduce these results with highly specific artificial BTK-targeting microRNA, 297 
miRBTK, introduced by lenti-virus. This suggests that it is BTK inhibition which is 298 
restoring bortezomib activity in bortezomib-resistant MM cells and not an off target 299 
effect of ibrutinib.   300 
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Multiple mechanisms of action of bortezomib have been described{Chauhan, 1996 301 
#8481},{Murray, 2014 #8633}, including the inhibition of BTK expression driven via 302 
repression of inducible NF-κB transcription factor translocation to the 303 
nucleus.{Rushworth, 2013 #6375;Yu, 2008 #8527;Dasmahapatra, 2013 #8642} We 304 
found enhanced nuclear localisation of NF-kB p65 in the bortezomib-resistant cells. 305 
This is in-keeping with previous reports that bortezomib-resistance in MM is 306 
conveyed through the NF-κB signalling network. For example; constitutive 307 
expression of NF-κB is frequently seen in bortezomib refractory primary patient 308 
samples.{Markovina, 2008 #8524} Furthermore, the acquisition of bortezomib-309 
resistance can follow up-regulation of heat shock protein (HSP)90 and HSP27, 310 
which, in their action as ubiquitin chaperones, facilitate the activation of NF-κB in 311 
MM.{Mitsiades, 2002 #8562;Navas, 2006 #8563} Active pBTK is also known to be 312 
essential for NF-κB activation and B cell survival.{Davis, 2010 #8526} Thus, there 313 
exists a positive auto-regulatory feedback loop that stimulates transcription of BTK 314 
via two functionally competent NF-κB p65 sites in the BTK promoter.{Yu, 2008 315 
#8527} Here we show that bortezomib-resistance in MM is associated with higher 316 
basal nuclear NF-κB p65 in bortezomib-resistant MM cells, which, in turn, is 317 
associated with a greater reliance on pBTK for survival. These observations suggest 318 
that BTK inhibition by ibrutinib may be useful in the clinical treatment of bortezomib-319 
resistant MM. 320 
Taken together, these results show that bortezomib-resistance observed in the clinic 321 
occurs, at least in part, because bortezomib-resistant MM cells lose the capacity to 322 
be influenced by the inhibition of BTK-driven NF-κB p65, and the consequent NF-κB 323 
p65-driven auto-regulation of BTK. Accordingly, introduction of ibrutinib to the 324 
treatment regimens of bortezomib-resistant MM patients may lead to enhanced cell 325 
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death of the bortezomib-resistant sub-clones through inhibition of this BTK/NF-κB 326 
p65 signalling axis. Here we provide a biologic and molecular rationale for the clinical 327 
evaluation of bortezomib and ibrutinib combination therapy in post-bortezomib 328 
relapsed MM, including patients that have previously been refractory to bortezomib.329 
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Materials and Methods 330 
Materials 331 
All reagents were obtained from Sigma-Aldrich Co. (St. Louis, MO), unless stated 332 
otherwise. All MM/B-lymphoblast cell lines were obtained from the European 333 
Collection of Cell Cultures (ECCC).  334 
Cell culture 335 
MM cell lines (H929, LP-1, RPMI-8228, and U266) were cultured in a humidified 336 
atmosphere at 37°C and 5% (v/v) CO2 in RPMI-1640 media +L-Glutamine (Gibco 337 
Life Technologies) supplemented with 10 % (v/v) foetal bovine serum ([FBS]; 338 
Biosera). Bortezomib-resistant cells were cultured as above but supplemented with 339 
20 % (v/v) FBS. Bortezomib-resistance was selected for by dose escalation of a 340 
once-weekly bortezomib treatment, through 0.5, 1, 2.5 and 5 nM, until cells could 341 
tolerate 10 nM bortezomib (10-15 weeks; confirmed by luminescent cell viability 342 
assay). Each concentration was maintained for approximately 2-3 weeks to allow for 343 
proliferation of bortezomib-resistant sub-clones. Build-up of cell debris due to the 344 
high level of cell death was removed by centrifugation at 300g for 5 minutes before 345 
gently removing the supernatant and re-suspending the pellet. 346 
Primary MM cells were obtained under local ethical approval (LREC ref. 347 
07/H0310/146) and were isolated from the bone marrow aspirates of MM patients, as 348 
described previously.{Rushworth, 2013 #6375} Primary MM cells from bortezomib-349 
relapsed patients were not exposed to further bortezomib treatment until 350 
experimentation.  351 
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Ibrutinib ‘pulse’ treatment 352 
To mimic in vivo pharmacokinetics of rapid adsorption and elimination of the 353 
irreversible BTK inhibitor ibrutinib{Byrd, 2013 #8478}, we employed a method of 354 
‘pulse’ exposure to physiologically relevant levels of ibrutinib in vitro, as described 355 
previously.{Honigberg, 2010 #8631} Briefly, cells were exposed to 500 nM ibrutinib 356 
for 1 h before washing, followed by any additional drug treatment or assay in fresh 357 
media. 358 
Luminescent cell viability assay and chymotrypsin-like proteasome activity assay 359 
1x105 MM cells were treated as indicated. Relative cell viability was assayed using 360 
the CellTiter-Glo® Luminescent Cell Viability Assay (Promega), as per the 361 
manufacturer’s instructions. Proteasome activity was measured using the 362 
Proteasome-Glo™ Chymotrypsin-Like Cell-Based Assay (Promega), as per the 363 
manufacturer’s instructions. Luminescence was measured with the FLUOstar 364 
Omega Microplate Reader (BMGLabtech) and calculated as relative to untreated 365 
control samples. 366 
Quantification of protein activity and subcellular localisation by immunocytochemistry 367 
Relative activity of phosphorylated versus total BTK (pBTK vs. BTK), and subcellular 368 
distribution of nuclear vs. cytoplasmic NF-κB p65 (nuc. vs. cyt. p65) were analysed 369 
by immunocytochemistry. Briefly, 2 x 104 U266 MM cells were fixed onto microscope 370 
slides using the CytoSpin 4 Cytocentrifuge system (Thermo Fisher Scientific) and 4 371 
% (w/v) paraformaldehyde (PFA). Fixed cells were incubated with rabbit anti-human 372 
primary mAbs against pBTK (Tyr223) and goat anti-human primary mAbs against 373 
total BTK, or goat anti-human primary mAbs against NF-κB p65 (Cell Signalling 374 
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Technology). Cells were then incubated with Alexa Fluor® goat anti-rabbit and rabbit 375 
anti-goat IgG (H+L) secondary antibodies (Molecular Probes Life Technologies), or 376 
rabbit anti-goat IgG alone, respectively. Nuclei were localised by 4',6-diamidino-2-377 
phenylindole (DAPI) staining. After mounting, cells were viewed using the Axio 378 
Imager.D2 microscope and Axiovision software (Carl Zeiss Microscopy).  379 
Image analyses and quantification of pBTK vs. BTK, and nuc. vs. cyt. p65 staining 380 
intensity was performed using ImageJ 1.46 software (National Institute of Health) 381 
and plugins, as described previously.{Rushworth, 2014 #8589} Briefly, a threshold of 382 
staining intensity was applied and the area above the threshold (pixles2) was 383 
measured (n≥80 [BTK] and n≥20 [NF-κB] individual cells). Staining intensity (pixles2) 384 
was converted to a percentage as follows: pBTK/total BTK (%), or, 385 
nuclear/[cytoplasmic + nuclear NF-κB p65] (%). 386 
Western Immunoblotting 387 
Protein fractions of equal total protein concentration were extracted from U266 MM 388 
cells using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher 389 
Scientific) according to the manufacturer’s instructions. SDS/PAGE and western 390 
immunoblot analyses were performed as described previously{Rushworth, 2010 391 
#5374}. ECL detection using Pierce ECL Western Blotting Substrate (Thermo Fisher 392 
Scientific) and subsequent quantification were performed with the ChemiDoc-It2 393 
Imaging System (UVP). 394 
RNA extraction and quantitative real time-PCR 395 
Total RNA was extracted from 1 x 106 U266 MM cells using Total RNA Lysis Solution 396 
(Applied Biosystems-Life Technologies) according to the manufacturer’s instructions. 397 
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Reverse transcription of total RNA was performed using the GeneAmp® Gold RNA 398 
PCR Core Kit (Applied Biosystems-Life Technologies). Resultant cDNA was 399 
analysed by quantitative real-time PCR (qRT-PCR) using LightCycler® 480 SYBR 400 
Green I Master mix (Roche) and qRT-PCR primers for GAPDH [forward 5′-401 
ACCAGCCTCAAGATCATCAGC-3′ and reverse 5′-TGCTAAGCAGTTGGTGGTGC-402 
3′], BTK [forward 5′-CACACAGGTGAACTCCAGAAAG-3’ and reverse 5’-403 
AGAGATACTGCCCATCGATCCAGA-3’] and NF-κB p65 [forward 5′-404 
ACCGCTGCATCCACAGTT-3′ and reverse 5′-GGATGCGCTGACTGATAGC-3′] 405 
(Invitrogen-Life Technologies), on the LightCycler® 480 Real-Time PCR system 406 
(Roche), as previously described.{Murray, 2013 #8580} Gene expression was 407 
analysed using the comparative cycle threshold algorithm (ΔΔCT); mRNA expression 408 
was standardised against GAPDH expression.  409 
Lenti-virus construction and infection 410 
Lenti-virus containing artificial exogenous microRNA (miRNA) sequences targeting 411 
human NF-κB p65 (miR-p65 [5′-TACGTTTCTCCTCAATCCGGT-3′]), BTK (miR-BTK 412 
[5′-TTCACTGGACTCTTCACCTCT-3′]) or a control/scrambled sequence (miR-NEG), 413 
and an EmGFP–pre-miRNA encoding fragment, were constructed and produced as 414 
described previously.{Rushworth, 2014 #8589} Briefly, artificial miRNA targets were 415 
identified and designed to interact with the relevant exon using Block-iT RNAi 416 
designer software (Invitrogen). This ensures high specificity of miR-p65 and miR-417 
BTK, with no 3’UTR interaction, unlike endogenous miRNAs. 418 
5 x 105 U266 MM cells were infected and transduced with each lenti-virus (MOI: 15), 419 
in serum-free medium with 8 µg/mL Polybrene™. Following infection and before 420 
experimentation, transduced cells were analysed for target knock-down and 421 
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efficiency by qRT-PCR for BTK and NF-κB p65, and flow cytometry to detect GFP 422 
using the Accuri-C6 flow cytometer (BD Biosciences).  423 
Generation and transfection of the wild-type human BTK promoter-luciferase reporter 424 
construct 425 
To generate the wild-type human BTK promoter-luciferase reporter construct 426 
(pGL4.BTK), the BTK promoter region, including two innate κB binding sites, was 427 
amplified from genomic DNA via PCR with specific forward [5′-428 
TATCTCGAGGAAGAAAAGAGCCTGGGCA-3′] and reverse [5′-429 
ATAAGATCTGTCTTTTTTTCTTCTCAGCAGCA-3′] primers. The amplified fragment 430 
was cloned into the Xho I/Bgl II site of the Promoterless Firefly Luciferase 431 
‘pGL4.11[luc2P]‘ Vector, according to the manufacturers’ instructions (Promega).  432 
U266 MM cells were co-transfected with a total of 1 μg DNA, composed of the 433 
pGL4.BTK promoter-luciferase reporter construct and a pRL-TK Renilla Luciferase 434 
Control Reporter Vector (Promega) using FuGENE® HD Transfection Reagent 435 
(Promega) and incubated for 24 h at 37°C and 5% (v/v) CO2 before any further 436 
treatment.  437 
Chemi-luminescent luciferase reporter assay  438 
Firefly and Renilla promoter-luciferase reporter activity was analysed and quantified 439 
sequentially in a single sample with the Dual-Luciferase® Reporter Assay System 440 
(Promega), according to the manufacturer’s instructions, and the EnVision 2103 441 
Multilabel Plate Reader (Perkin Elmer). 442 
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Figures 451 
Figure 1. Characterisation of bortezomib-resistant MM cell lines, and primary 452 
relapsed MM patient samples. (A) The IC
50
 Log[bortezomib] (nM) of bortezomib-453 
naïve and bortezomib-resistant MM cell lines was analysed by luminescent cell 454 
viability assay. (B) Relative cell viability (5 nM/48 h) and (C) chymotrypsin-like 455 
proteasome activity in bortezomib-naïve and bortezomib-resistant MM cell lines in 456 
response to (5 nM/4 h) bortezomib. (D) Relative cell viability of primary naïve and 457 
primary relapsed MM patient samples in response to bortezomib (5 nM/24 h). 458 
Statistical significance between treatments was calculated by Student’s t test; * 459 
indicates p ≤ 0.05. Statistical significance between cohorts was calculated by 460 
ANOVA; # indicates p ≤ 0.05. 461 
 462 
Figure 2. Enhanced BTK activity in bortezomib-resistant MM cell lines is 463 
resistant to inhibition with bortezomib. (A) Representative immunocytochemistry 464 
of basal levels of total and phosphorylated BTK (pBTK) in bortezomib-naïve and 465 
bortezomib-resistant U266 MM cells with DAPI nuclear staining [left panel] and 466 
subsequent quantification of basal pBTK/total BTK (%) staining intensity [right panel]. 467 
Box and whisker indicates the mean ± SEM (n ≥ 80). (B) qRT-PCR analysis of BTK 468 
mRNA following bortezomib (5 nM/4 h) exposure in bortezomib-naïve and 469 
bortezomib-resistant U266 MM cells relative to GAPDH. Values indicate the mean ± 470 
SEM from 3 independent experiments. (C) Representation of wild type pGL4.BTK 471 
promoter-luciferase vector [including κB binding sites] transfected into bortezomib-472 
naïve and bortezomib-resistant U266 MM cells. (D) Luciferase activity of pGL4.BTK 473 
promoter-luciferase vectors in bortezomib-naïve and bortezomib-resistant U266 MM 474 
cells following bortezomib (5 nM/24 h) exposure, normalised by co-transfection with 475 
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pRL-TK Renilla Luciferase Reporter Vectors. Values indicate the mean ± SEM from 3 476 
independent experiments. Statistical significance between treatments was calculated 477 
by Student’s t test; * indicates p ≤ 0.05. Statistical significance between cohorts was 478 
calculated by ANOVA; # indicates p ≤ 0.01.  479 
 480 
Figure 3. BTK inhibition enhances sensitivity to bortezomib in bortezomib-481 
naïve and bortezomib-resistant MM cells.  (A) Relative cell viability of bortezomib-482 
naïve and bortezomib-resistant MM cell lines 48 h post-ibrutinib ‘pulse’ treatment. (B) 483 
Relative cell viability of bortezomib-naïve and bortezomib-resistant MM cells post-484 
ibrutinib ‘pulse’ treatment in combination with bortezomib (5 nM/24 h). (C) Relative 485 
cell viability of primary naïve and primary relapsed MM patient samples post in vitro 486 
ibrutinib ‘pulse’ treatment in combination with bortezomib (5 nM/24 h). Statistical 487 
significance between treatments was calculated by Student’s t test; * indicates p ≤ 488 
0.05. Statistical significance between cohorts was calculated by ANOVA; # indicates 489 
p ≤ 0.01. 490 
 491 
Figure 4. BTK inhibition via lenti-viral miRNA targeting enhances sensitivity to 492 
bortezomib in bortezomib-naïve and bortezomib-resistant MM cells.  (A) qRT-493 
PCR analysis of basal BTK mRNA expression in bortezomib-naïve and bortezomib-494 
resistant MM U266 cells infected with lenti-viral miRNA constructs targeting BTK 495 
(miRBTK) transcription relative to GAPDH. (B) Relative cell viability of bortezomib-496 
naïve and bortezomib-resistant MM U266 cells infected with lenti-viral miRBTK 497 
before and after bortezomib treatment (5 nM/24 h). Values indicate the mean ± SEM 498 
from 3 independent experiments. Statistical significance between treatments was 499 
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calculated by Student’s t test; * indicates p ≤ 0.05. Statistical significance between 500 
cohorts was calculated by ANOVA; # indicates p ≤ 0.01. 501 
 502 
Figure 5. Bortezomib-resistance is driven by enhanced NF-κB p65 activity and 503 
can be reversed by BTK inhibition. (A) Quantification of staining intensity of 504 
nuclear p65/total NF-κB p65 (%) in bortezomib-naïve and bortezomib-resistant U266 505 
MM cells. Box and whisker indicates the mean ± SEM (n ≥ 20). Statistical 506 
significance between cohorts was calculated by ANOVA; # indicates p ≤ 0.01. Inset 507 
shows example immunocytochemistry for NF-κB p65. Dotted line indicates nucleus 508 
as determined by DAPI staining. (B) Western immunoblot of bortezomib-naïve [N] 509 
and bortezomib-resistant [R] U266 nuclear [Nuc.] and cytoplasmic [Cyt.] cell 510 
fractions. GAPDH and Histone 3 [H3] show equal loading for cyt. and nuc. fractions, 511 
respectively. (C) Quantification of staining intensity of nuclear NF-κB p65/total NF-κB 512 
p65 (%) in bortezomib-naïve and bortezomib-resistant U266 MM cells. Box and 513 
whisker indicates the mean ± SEM (n ≥ 20). Statistical significance between cohorts 514 
was calculated by ANOVA; # indicates p ≤ 0.05. (D) qRT-PCR analysis of basal NF-515 
κB p65 mRNA expression in bortezomib-naïve and bortezomib-resistant MM U266 516 
cells infected with lenti-viral miRNA constructs targeting NF-κB p65 (miRp65) 517 
transcription relative to GAPDH. (E) Relative cell viability of bortezomib-naïve and 518 
bortezomib-resistant MM U266 cells infected with lenti-viral miRp65 24 h following 519 
ibrutinib ‘pulse’ treatment. Values indicate the mean ± SEM from 3 independent 520 
experiments. Statistical significance between treatments was calculated by Student’s 521 
t test; * indicates p ≤ 0.05. Statistical significance between cohorts was calculated by 522 
ANOVA; # indicates p ≤ 0.01. 523 
